DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the U.S. between DePuy Synthes Sales, Inc. and Prosidyan to promote the FIBERGRAFT Family of Products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for optimal resorption in clinical use during spine fusion surgery. By adding FIBERGRAFT to its offerings, DePuy Synthes will further enhance the company’s biomaterials portfolio for spine, which currently includes cellular allograft, demineralized bone matrix, and first generation synthetic solutions. Surgeons will now have a broad range of handling options based on the needs of each patient and surgical case.
Approximately 400,000 patients in the U.S. undergo spinal fusion surgery annually to help reduce pain and nerve root inflammation. Surgeons will often use a biomaterial to facilitate bone growth and fusion. Each case is unique, and providing a broad portfolio of offerings allows surgeons the opportunity to select the right consistency.
“Our exclusive agreement with Prosidyan allows us to complete our biomaterials offering through a next generation synthetic solution and provide our customers with a variety of options based on handling preference and needs of their patients,” says Juan-José Gonzalez, President, DePuy Synthes U.S. “This offering allows us to provide a more complete solution for our customers.”
Prosidyan was founded in 2009 to develop a family of synthetic bioactive bone graft substitutes based on microsized fibers of bioactive glass. Prosidyan’s first product, FIBERGRAFT BG Morsels, a synthetic bone graft substitute, received FDA clearance in March 2014, and the first surgery utilizing this innovative bone substitute was performed in May 2014. The firm’s second product in the line, FIBERGRAFT BG Putty, received FDA clearance in March 2015, and comprises FIBERGRAFT BG Morsels delivered through Prosidyan’s proprietary bioactive carrier, OSSIGLIDE. Prosidyan’s third and flagship product FIBERGRAFT BG Matrix, received FDA clearance in October of 2017 and comprised FIBERGRAFT BG Morsels combined with Prosidyan’s proprietary type I collagen based bioactive carrier.
To date, FIBERGRAFT products have been provided for more than 10,000 patients across the U.S.